【摘要】 评价瑞舒伐他汀对缺血性卒中患者血清脂质、炎性因子及颈动脉粥样硬化斑块的影响。共98例急性缺血性卒中伴颈动脉粥样硬化患者应用瑞舒伐他汀10 mg,睡前顿服。连续治疗6个月后分别测定血清超敏C.反应蛋白、肿瘤坏死因子.α及血清脂质变化,对比颈动脉内.中膜厚度,计算颈动脉粥样硬化斑块积分。结果显示,瑞舒伐他汀治疗6个月后患者血清超敏C.反应蛋白、肿瘤坏死因子.α及血清脂质水平下降(P<0.01);颈动脉粥样硬化斑块总数减少、稳定性斑块数目有所增加、颈动脉内.中膜厚度及颈动脉粥样硬化斑块积分下降(P<0.05)。提示瑞舒伐他汀具有抗炎及改善颈动脉粥样硬化斑块程度的作用。更多还原

【Abstract】 Carotid atherosclerosis is closely related with ischemic stroke occurrence, development and recurrence. This study aims to make an evaluation of the effects of rosuvastatin on inflammatory factors, serum lipid and carotid atherosclerotic plaque in patients with acute ischemic stroke. In this study, 98 patients with acute ischemic stroke and carotid atherosclerosis were given oral administration of rosuvastatin calcium(10 mg once every night), and the course of treatment was 6 months. After treatment, the changes of serum high.sensitivity C.reactive protein(hs.CRP), tumor necrosis factor.alpha(TNF.α) and blood lipid were measured, as well as carotid atherosclerotic intima. media thickness(IMT) and the calculation of carotid atherosclerotic plaque score. According to the examination results, after 6 months’ treatment with rosuvastatin, serum hs.CRP, TNF.α, total cholesterol(TC), triglyceride(TG) and low.density lipoprotein cholestrol(LDL.C) decreased significantly(P < 0.01, for all), while high.density lipoprotein cholestrol(HDL.C) increased significantly(P < 0.01); the total number of plaque reduced, while the number of stable plaque increased(P < 0.05); carotid artery IMT and carotid artery plaque score decreased significantly(P < 0.05). There were significant differences between before and after treatment. The results of this study show that rosuvastatin plays a role in anti.inflammation and alleviates the degree of carotid atherosclerotic plaque.更多还原